| scholarly article | Q13442814 |
| P50 | author | Wei Cui | Q41903793 |
| P2093 | author name string | Akhurst RJ | |
| Balmain A | |||
| Ireland H | |||
| Bryson S | |||
| Fowlis DJ | |||
| Duffie E | |||
| P2860 | cites work | Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability | Q24319995 |
| Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction | Q28284617 | ||
| Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential | Q33825657 | ||
| Mammary tumor suppression by transforming growth factor beta 1 transgene expression | Q34316245 | ||
| Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene | Q34593947 | ||
| Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro | Q35610349 | ||
| Carcinosarcoma of the lung; review of the literature and report of two cases treated by pneumonectomy | Q35661885 | ||
| Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution | Q35817740 | ||
| Concerted action of TGF-beta 1 and its type II receptor in control of epidermal homeostasis in transgenic mice | Q72297295 | ||
| Targeted deletion of the TGF-beta 1 gene causes rapid progression to squamous cell carcinoma | Q72801082 | ||
| In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states | Q72818153 | ||
| Transforming growth factor-beta 1 as a signal for induction of cell death by apoptosis | Q35975984 | ||
| Stimulatory role of transforming growth factors in multistage skin carcinogenesis: possible explanation for the tumor-inducing effect of wounding in initiated NMRI mouse skin | Q36009391 | ||
| Distribution and modulation of the cellular receptor for transforming growth factor-beta | Q36217344 | ||
| Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes | Q36220190 | ||
| Integrin heterodimer and receptor complexity in avian and mammalian cells | Q36220327 | ||
| TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors | Q36235100 | ||
| Cell death by apoptosis and its protective role against disease | Q36327633 | ||
| Inhibition of skin development by overexpression of transforming growth factor beta 1 in the epidermis of transgenic mice | Q36345330 | ||
| Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion | Q36392971 | ||
| TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector | Q36530713 | ||
| Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1 | Q36531643 | ||
| Transforming growth factor-beta 3 is required for secondary palate fusion | Q37373842 | ||
| Secreted or nonsecreted forms of acidic fibroblast growth factor produced by transfected epithelial cells influence cell morphology, motility, and invasive potential | Q37467404 | ||
| Coordinated regulation of apoptosis and cell proliferation by transforming growth factor beta 1 in cultured uterine epithelial cells | Q37486376 | ||
| Escape from transforming growth factor beta control and oncogene cooperation in skin tumor development | Q37611617 | ||
| A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance | Q37699443 | ||
| Mesoderm induction in Xenopus caused by activation of MAP kinase | Q38293549 | ||
| Spindle cell squamous carcinomas and sarcoma-like tumors of the skin: a comparative study of 38 cases | Q40361204 | ||
| Transgenic Approaches to the Analysis of ras and p53 Function in Multistage Carcinogenesis | Q40431247 | ||
| Autocrine transforming growth factor beta 1 modulates the expression of integrin alpha 5 beta 1 in human colon carcinoma FET cells | Q41335793 | ||
| Complex patterns of expression suggest extensive roles for the α2β1 integrin in murine development | Q41478595 | ||
| Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. | Q41552765 | ||
| Expression of alpha 6 beta 4 integrin increases during malignant conversion of mouse epidermal keratinocytes: association of beta 4 subunit to the cytokeratin fraction | Q41611433 | ||
| Regulation of human colon-carcinoma cell adhesion to extracellular matrix by transforming growth factor beta 1 | Q41631134 | ||
| TGF-beta 1 and skin carcinogenesis: antiproliferative effect in vitro and TGF-beta 1 mRNA expression during epidermal hyperproliferation and multistage tumorigenesis | Q41706662 | ||
| The conversion of mouse skin squamous cell carcinomas to spindle cell carcinomas is a recessive event | Q42218126 | ||
| Involvement of p21ras in Xenopus mesoderm induction | Q42819317 | ||
| Induction of papillomas with a high probability of conversion to malignancy | Q44144119 | ||
| Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta | Q44225473 | ||
| Changes in response to, and production of, transforming growth factor type beta during neoplastic progression in cultured rat tracheal epithelial cells | Q44751226 | ||
| Spindle cell carcinoma.Ultrastructural evidence of squamous origin and collagen production by the tumor cells | Q44962271 | ||
| Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. | Q45989344 | ||
| Aberrant expression during two-stage mouse skin carcinogenesis of a type I 47-kDa keratin, K13, normally associated with terminal differentiation of internal stratified epithelia. | Q53524991 | ||
| Keratins as markers of malignancy in mouse epidermal tumors | Q53577413 | ||
| Localized production of TGF-β mRNA in tumour promoter-stimulated mouse epidermis | Q59068394 | ||
| Differential expression of genes encoding TGFs β1, β2, and β3 during murine palate formation | Q67672314 | ||
| Immunolocalization of epidermal growth factor (EGF), EGF receptor and transforming growth factor alpha (TGF alpha) during murine palatogenesis in vivo and in vitro | Q68026026 | ||
| Multistage chemical carcinogenesis protocols produce spindle cell carcinomas of the mouse skin | Q69108506 | ||
| Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor beta | Q69650317 | ||
| Sarcomatoid squamous cell carcinoma of the mucous membranes of the head and neck: a clinicopathologic study of 20 cases | Q70902588 | ||
| Expression pattern of the cell adhesion molecules. E-cadherin, P-cadherin and alpha 6 beta 4 intergrin is altered in pre-malignant skin tumors of p53-deficient mice | Q70913851 | ||
| Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer | Q71601446 | ||
| Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes | Q71604126 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 531-542 | |
| P577 | publication date | 1996-08-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice | |
| P478 | volume | 86 |
| Q24312492 | A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis |
| Q35193411 | A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras |
| Q34781180 | A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis |
| Q39033867 | Albumin acts like transforming growth factor β1 in microbubble-based drug delivery |
| Q83320051 | Alterations of Smad expression and activation in defining 2 subtypes of human head and neck squamous cell carcinoma |
| Q46388144 | Altered expression of TGF-beta receptors in hepatocellular carcinoma--effects of a constitutively active TGF-beta type I receptor mutant |
| Q47349304 | Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis |
| Q37102288 | An activating beta1 integrin mutation increases the conversion of benign to malignant skin tumors. |
| Q38831902 | Areca nut alkaloids induce irreparable DNA damage and senescence in fibroblasts and may create a favourable environment for tumour progression |
| Q33568163 | Association between TGFBR1*6A and osteosarcoma: a Chinese case-control study |
| Q36612227 | Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation |
| Q24545375 | Autocrine PDGFR signaling promotes mammary cancer metastasis |
| Q41031197 | Autocrine secretion of TGF-beta 1 and TGF-beta 2 by pre-adipocytes and adipocytes: a potent negative regulator of adipocyte differentiation and proliferation of mammary carcinoma cells |
| Q40858455 | Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas |
| Q34792468 | Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. |
| Q41915296 | CCT6A suppresses SMAD2 and promotes prometastatic TGF-β signaling |
| Q34984681 | CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells |
| Q41636608 | Cancer cells remodel themselves and vasculature to overcome the endothelial barrier. |
| Q36092823 | Carcinogenesis, cancer therapy and chemoprevention |
| Q40439634 | Characterization of murine S-endoglin isoform and its effects on tumor development. |
| Q36857846 | Chromatin structure regulation in transforming growth factor-beta-directed epithelial-mesenchymal transition |
| Q53636593 | Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}. |
| Q30409676 | Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells |
| Q41808886 | Complex Regulation of the Pericellular Proteolytic Microenvironment during Tumor Progression and Wound Repair: Functional Interactions between the Serine Protease and Matrix Metalloproteinase Cascades |
| Q27693607 | Complexities of TGF-β targeted cancer therapy |
| Q33930015 | Conditional epidermal expression of TGFbeta 1 blocks neonatal lethality but causes a reversible hyperplasia and alopecia |
| Q43630638 | Conditional expression of the dominant-negative TGF-β receptor type II elicits lingual epithelial hyperplasia in transgenic mice |
| Q36017569 | Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells |
| Q77668100 | Correlation between plasma transforming growth factor-beta 1 and second primary breast cancer in a chemoprevention trial |
| Q39965380 | Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model |
| Q53426083 | Cyclosporine induces cancer progression by a cell-autonomous mechanism. |
| Q38167292 | Cytoplasmic PML: from molecular regulation to biological functions |
| Q29616379 | Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer |
| Q36296488 | DMA(V) in Drinking Water Activated NF-κB Signal Pathway and Increased TGF-β and IL-1β Expressions in Bladder Epithelial Cells of Rats |
| Q37044614 | Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression |
| Q40887247 | Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras |
| Q37978661 | Dermal mast cells affect the development of sunlight-induced skin tumours. |
| Q33594775 | Desmoplasia in different degrees of invasion of carcinoma ex-pleomorphic adenoma |
| Q35929445 | Development and possible clinical use of antagonists for PDGF and TGF-beta |
| Q35968389 | Development of TGF-beta signalling inhibitors for cancer therapy |
| Q48148598 | Developmentally regulated signaling pathways in glioma invasion. |
| Q39027205 | Dichotomous roles of TGF-β in human cancer |
| Q40537092 | Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis |
| Q37401479 | Direct cancer-stromal interaction increases fibroblast proliferation and enhances invasive properties of scirrhous-type gastric carcinoma cells. |
| Q33840435 | Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis |
| Q53376881 | Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. |
| Q79120868 | Downregulation of TGFβ isoforms and their receptors contributes to keratinocyte hyperproliferation in psoriasis vulgaris |
| Q54672329 | Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. |
| Q39517290 | EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells |
| Q33614767 | Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients |
| Q37806003 | Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition |
| Q47677944 | Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells |
| Q24540358 | Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. |
| Q40848929 | Epithelial carcinogenesis in the mouse: correlating the genetics and the biology |
| Q37620379 | Epithelial-mesenchymal transition in development and cancer |
| Q35884866 | Epithelial-mesenchymal transition in oral squamous cell carcinoma |
| Q27860487 | Epithelial-mesenchymal transitions in tumour progression |
| Q36964214 | Exosome-mediated transfer from the tumor microenvironment increases TGFβ signaling in squamous cell carcinoma |
| Q42152135 | Expression of alpha(v)beta6 integrin in oral leukoplakia |
| Q42020365 | Expression of the Arf tumor suppressor gene is controlled by Tgfbeta2 during development |
| Q42447077 | Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis. |
| Q53677585 | Expression of transforming growth factor (TGF)-beta1 and TGF-beta type II receptor in preneoplastic lesions during chemical hepatocarcinogenesis of rats. |
| Q54127845 | Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. |
| Q37376265 | FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis |
| Q35154337 | FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer |
| Q40691694 | Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. |
| Q36455977 | Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia |
| Q34691678 | From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells |
| Q40007539 | Functional blockade of Smad4 leads to a decrease in beta-catenin levels and signaling activity in human pancreatic carcinoma cells |
| Q74298040 | Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4 |
| Q34085928 | Functional proteomics of transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFbeta1-dependent regulation of DNA repair |
| Q24301339 | GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition |
| Q35119392 | Genealogy, expression, and cellular function of transforming growth factor-β |
| Q33643339 | Genetic events and the role of TGF beta in epithelial tumour progression |
| Q36232185 | Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta |
| Q34650188 | Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. |
| Q39332689 | Genomic organization and modulation of gene expression of the TGF-β and FGF pathways in the allotetraploid frog Xenopus laevis |
| Q37602543 | Glioblastoma Multiforme Oncogenomics and Signaling Pathways |
| Q35919080 | HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis |
| Q24318681 | HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition |
| Q28365742 | Healing of burn wounds in transgenic mice overexpressing transforming growth factor-beta 1 in the epidermis |
| Q43163564 | Heterogeneous activation of the TGFbeta pathway in glioblastomas identified by gene expression-based classification using TGFbeta-responsive genes |
| Q38288726 | High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling |
| Q39768636 | Hypoxia-activated Smad3-specific dephosphorylation by PP2A. |
| Q35157258 | Identification of genetic loci that control mammary tumor susceptibility through the host microenvironment. |
| Q28390399 | Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients |
| Q33929706 | Impaired prostate tumorigenesis in Egr1-deficient mice |
| Q36617606 | Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines |
| Q41043037 | Induction of mutual stabilization and retardation of tumor growth by coexpression of plakoglobin and E-cadherin in mouse skin spindle carcinoma cells |
| Q36732552 | Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. |
| Q41967034 | Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis |
| Q33643327 | Insights into cancer from transgenic mouse models |
| Q37258903 | Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition |
| Q36448966 | Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis |
| Q24793548 | Interfering with TGFbeta-induced Smad3 nuclear accumulation differentially affects TGFbeta-dependent gene expression |
| Q40725068 | Involvement of cell-cell interactions in the rapid stimulation of Cas tyrosine phosphorylation and Src kinase activity by transforming growth factor-beta 1. |
| Q34334857 | It takes a tissue to make a tumor: epigenetics, cancer and the microenvironment |
| Q35861493 | Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation |
| Q35747946 | Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation |
| Q43148137 | Liver stem cells and molecular signaling pathways in hepatocellular carcinoma |
| Q39460658 | Loss of JunB activity enhances stromelysin 1 expression in a model of the epithelial-to-mesenchymal transition of mouse skin tumors |
| Q30482281 | Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia |
| Q35627068 | Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma |
| Q36843021 | Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis |
| Q33728014 | Loss of the p53/p63 Regulated Desmosomal Protein Perp Promotes Tumorigenesis |
| Q42468494 | MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice. |
| Q34136498 | Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape |
| Q52196601 | Mapping of a major genetic modifier of embryonic lethality in TGF beta 1 knockout mice. |
| Q35185712 | Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling. |
| Q36490750 | Mechanisms of immune evasion by tumors |
| Q54297451 | Metastasis is driven by sequential elevation of H-ras and Smad2 levels. |
| Q42589687 | Molecular mechanisms of mouse skin tumor promotion |
| Q33909842 | Molecular mechanisms of osteolytic bone metastases |
| Q34421762 | Mouse models for multistep tumorigenesis |
| Q38337029 | Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. |
| Q38069778 | Non-melanoma skin cancer in mouse and man. |
| Q41124260 | Notch intracellular domain expression in various skin fibroproliferative diseases |
| Q79851747 | Novel functional single nucleotide polymorphisms in the latent transforming growth factor-beta binding protein-1L promoter: effect on latent transforming growth factor-beta binding protein-1L expression level and possible prognostic significance in |
| Q43690863 | Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases |
| Q33889211 | OVOL2 antagonizes TGF-β signaling to regulate epithelial to mesenchymal transition during mammary tumor metastasis. |
| Q40849516 | Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III. |
| Q36947046 | Oncogenic Ras and transforming growth factor-beta synergistically regulate AU-rich element-containing mRNAs during epithelial to mesenchymal transition. |
| Q34126792 | Oncogenic resistance to growth-limiting conditions |
| Q41107314 | Opposite effect of stable transfection of bioactive transforming growth factor-beta 1 (TGF beta 1) versus exogenous TGF beta 1 treatment on expression of 92-kDa type IV collagenase in mouse skin squamous cell carcinoma CH72 cells. |
| Q34687503 | Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. |
| Q40573488 | Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility |
| Q40906841 | Overexpression of a dominant-negative type II TGFbeta receptor tagged with green fluorescent protein inhibits the effects of TGFbeta on cell growth and gene expression of mouse adrenal tumor cell line Y-1 and enhances cell tumorigenicity. |
| Q43830995 | Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members |
| Q55037666 | Overexpression of latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) in association with TGF-beta 1 in ovarian carcinoma. |
| Q33693105 | PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma |
| Q41857137 | PAI-1 is a Critical Upstream Regulator of the TGF-beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma |
| Q39709591 | PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes |
| Q53561253 | PIN1, the cell cycle and cancer. |
| Q39924024 | PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production |
| Q38357026 | Pancreatic carcinoma cell lines with SMAD4 inactivation show distinct expression responses to TGFB1. |
| Q47329309 | Paradoxical roles of TGF-β signaling in suppressing and promoting squamous cell carcinoma |
| Q33683599 | Pathological relevance of epithelial and mesenchymal phenotype plasticity |
| Q34162969 | Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. |
| Q35053451 | Pharmacologic inhibition of ALK5 causes selective induction of terminal differentiation in mouse keratinocytes expressing oncogenic HRAS. |
| Q33760899 | Photopheresis: clinical applications and mechanism of action |
| Q28535093 | Platelet P2Y12 is involved in murine pulmonary metastasis |
| Q33918198 | Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy |
| Q64882364 | Proteins involved in cutaneous basal cell carcinoma development. |
| Q24620175 | Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type |
| Q40757186 | Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways |
| Q55013837 | Ras enhances TGF-β signaling by decreasing cellular protein levels of its type II receptor negative regulator SPSB1. |
| Q34646656 | Recent advances in cancer research: mouse models of tumorigenesis |
| Q39958524 | Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. |
| Q51734226 | Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma. |
| Q35584927 | Regulation of matrix metalloproteinases: an overview |
| Q36996297 | Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. |
| Q38216012 | Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection |
| Q39921205 | Restoring TGFbeta function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation. |
| Q35156138 | Resveratrol targets transforming growth factor-β2 signaling to block UV-induced tumor progression |
| Q33958096 | Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein |
| Q33964689 | Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells |
| Q35170428 | Role of tissue stroma in cancer cell invasion |
| Q34136011 | Role of transforming growth factor beta in cancer |
| Q35019137 | Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer |
| Q36677493 | Role of transforming growth factor-beta in cancer progression |
| Q84562881 | Role of transforming growth factor-β1 -509 C/T promoter polymorphism in gastric cancer in south Indian population |
| Q37027389 | Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling. |
| Q36921552 | Roles of Smad3 in TGF-beta signaling during carcinogenesis |
| Q37339711 | Roles of TGFbeta in metastasis |
| Q34928876 | STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer. |
| Q63641070 | Sialylation of vasorin by ST3Gal1 facilitates TGF-β1-mediated tumor angiogenesis and progression |
| Q25257731 | Signal processing in the TGF-beta superfamily ligand-receptor network |
| Q45314392 | Signaling by TGF-beta Receptor Complex in Cancer |
| Q36077746 | Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection |
| Q37603444 | Smad3-related miRNAs regulated oncogenic TRIB2 promoter activity to effectively suppress lung adenocarcinoma growth |
| Q44308474 | Smad4 as a transcription corepressor for estrogen receptor alpha |
| Q30476201 | Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses |
| Q74688277 | Smad4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells |
| Q38345085 | Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta |
| Q33596982 | Smad4-mediated TGF-beta signaling in tumorigenesis |
| Q24649660 | Smad7 induces hepatic metastasis in colorectal cancer |
| Q42503191 | Smads mediate signaling of the TGFbeta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis |
| Q28572344 | Snail blocks the cell cycle and confers resistance to cell death |
| Q33846215 | Stem cells: the intestinal stem cell as a paradigm. |
| Q37696223 | Suppression of skin tumorigenesis in CD109-deficient mice |
| Q34414642 | Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis |
| Q46196856 | Systems genetics analysis of cancer susceptibility: from mouse models to humans |
| Q43617024 | T-Cell type acute lymphoblastic leukemia following cyclosporin A therapy for aplastic anemia |
| Q28594881 | TGF beta 1 inhibits Ca2+-calcineurin-mediated activation in thymocytes |
| Q34136526 | TGF-beta and colorectal carcinogenesis |
| Q29616456 | TGF-beta and epithelial-to-mesenchymal transitions |
| Q33734595 | TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition |
| Q41659039 | TGF-beta receptor signaling |
| Q33834762 | TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development |
| Q34421804 | TGF-beta signaling in cancer--a double-edged sword |
| Q29615427 | TGF-beta signaling in tumor suppression and cancer progression |
| Q28131770 | TGF-beta signalling from cell membrane to nucleus through SMAD proteins |
| Q36001319 | TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. |
| Q40727835 | TGF-beta(1) and Smad4 overexpression induce a less invasive phenotype in highly invasive spindle carcinoma cells |
| Q36241240 | TGF-beta, neuronal stem cells and glioblastoma |
| Q73046705 | TGF-beta-induced cell-cycle arrest through the p21(WAF1/CIP1)-G1 cyclin/Cdks-p130 pathway in gastric-carcinoma cells |
| Q29619820 | TGF-beta-induced epithelial to mesenchymal transition |
| Q42399810 | TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1. |
| Q43146931 | TGF-beta1-Induced Expression of the Poor Prognosis SERPINE1/PAI-1 Gene Requires EGFR Signaling: A New Target for Anti-EGFR Therapy |
| Q37573098 | TGF-beta3 and cancer: a review |
| Q36413606 | TGF-ß isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity |
| Q27025590 | TGF-β - an excellent servant but a bad master |
| Q36210115 | TGF-β and NF-κB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers |
| Q46183468 | TGF-β inhibits metastasis in late stage human squamous cell carcinoma of the skin by a mechanism that does not involve Id1 |
| Q35871985 | TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma |
| Q44411475 | TGF-β1 Regulates Lymphocyte Homeostasis by Preventing Activation and Subsequent Apoptosis of Peripheral Lymphocytes |
| Q37634488 | TGF-β: duality of function between tumor prevention and carcinogenesis. |
| Q33957710 | TGFBR1 and cancer susceptibility |
| Q45364293 | TGFBR3 polymorphisms and its haplotypes associated with chronic hepatitis B virus infection and age of hepatocellular carcinoma occurrence |
| Q28142605 | TGFbeta signaling in growth control, cancer, and heritable disorders |
| Q46272247 | TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis |
| Q35079908 | TGFbeta-regulated transcriptional mechanisms in cancer |
| Q28083107 | TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis |
| Q97867213 | TGFβ biology in cancer progression and immunotherapy |
| Q37777022 | TGFβ signaling in head and neck squamous cell carcinoma |
| Q35169582 | Targeting the TGF beta signaling network in human neoplasia |
| Q36462348 | Targeting the TGFβ signalling pathway in disease |
| Q28276556 | The Discovery and Early Days of TGF-β: A Historical Perspective |
| Q28542654 | The FYVE domain of Smad Anchor for Receptor Activation (SARA) is required to prevent skin carcinogenesis, but not in mouse development |
| Q36522719 | The Role of TGFβ Signaling in Squamous Cell Cancer: Lessons from Mouse Models |
| Q57816901 | The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity |
| Q37261631 | The TGF-beta paradox in human cancer: an update |
| Q24652992 | The basics of epithelial-mesenchymal transition |
| Q36462328 | The complexities of TGF-β action during mammary and squamous cell carcinogenesis |
| Q50082534 | The concomitant apoptosis and EMT underlie the fundamental functions of TGF-β. |
| Q51028639 | The effect of ultraviolet radiation on the transforming growth factor beta 1/Smads pathway and p53 in actinic keratosis and normal skin. |
| Q41469660 | The importance of context in cytokine action |
| Q33974545 | The influence of the microenvironment on the malignant phenotype |
| Q24532213 | The latent transforming growth factor beta binding protein (LTBP) family |
| Q33923770 | The potential influence of radiation-induced microenvironments in neoplastic progression |
| Q42342102 | The propensity for epithelial-mesenchymal transitions is dictated by chromatin states in the cancer cell of origin |
| Q35782195 | The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy |
| Q36241260 | The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer |
| Q35969342 | The role of TGF-beta in epithelial malignancy and its relevance to the pathogenesis of oral cancer (part II). |
| Q44888250 | The roles of Smad2 and Smad3 in the development of chemically induced skin tumors in mice |
| Q36784315 | The skinny on Slug |
| Q21195231 | The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta |
| Q58700178 | Three-Dimensional In Vitro Hydro- and Cryogel-Based Cell-Culture Models for the Study of Breast-Cancer Metastasis to Bone |
| Q35591715 | Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis |
| Q54104994 | Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. |
| Q40660373 | Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. |
| Q33884576 | Transforming growth factor beta1 enhances tumor promotion in mouse skin carcinogenesis |
| Q38132176 | Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer |
| Q57212391 | Transforming growth factor-[beta]1 -509T reduces risk of colorectal cancer, but not adenoma in Koreans |
| Q38338094 | Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer ce |
| Q24793319 | Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta |
| Q45074420 | Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival |
| Q37205559 | Transforming growth factor-beta in breast cancer: too much, too late |
| Q34438032 | Transforming growth factor-beta signal transduction in epithelial cells. |
| Q28138728 | Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines |
| Q40897760 | Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. |
| Q47852627 | Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. |
| Q24600173 | Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism |
| Q37633528 | Transforming growth factor-beta: a target for cancer therapy |
| Q41489951 | Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity |
| Q34789300 | Transforming growth factor-β and the hallmarks of cancer |
| Q39380641 | Transforming growth factor-β enhances invasion and metastasis in Ras-transfected human malignant epidermal keratinocytes |
| Q37315087 | Tumor suppressor and oncogene actions of TGFbeta1 occur early in skin carcinogenesis and are mediated by Smad3. |
| Q36516410 | Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer |
| Q41130519 | Uncoordinated regulation of mRNA expression of the three isoforms of transforming growth factor-beta in the mouse skin carcinogenesis model. |
| Q92800229 | Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies |
| Q34363852 | Use of a TGFβ type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFβ signaling in tumor promotion and progression |
| Q92783226 | Wnt Signaling Pathways in Keratinocyte Carcinomas |
| Q35189133 | ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor |
| Q47748656 | mTORC1 loss impairs epidermal adhesion via TGF-β/Rho kinase activation |
| Q64068516 | α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas |
| Q56999751 | α2-HS Glycoprotein/Fetuin, a Transforming Growth Factor-β/Bone Morphogenetic Protein Antagonist, Regulates Postnatal Bone Growth and Remodeling |
Search more.